KSCCM
Search
- Page Path
- HOME > Search
Original Article
- Pulmonary
- Are sodium-glucose co-transporter-2 inhibitors associated with improved outcomes in diabetic patients admitted to intensive care units with septic shock?
- Nikita Ashcherkin, Abdelmohaymin A. Abdalla, Simran Gupta, Shubhang Bhatt, Claire I. Yee, Rodrigo Cartin-Ceba
- Acute Crit Care. 2024;39(2):251-256. Published online May 14, 2024
- DOI: https://doi.org/10.4266/acc.2023.01046
- 11,398 View
- 223 Download
- 5 Web of Science
- 5 Crossref
-
Abstract
PDF - Background
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce organ dysfunction in renal and cardiovascular disease. There are limited data on the role of SGLT2i in acute organ dysfunction. We conducted a study to assess the effect of SGLT2i taken prior to intensive care unit (ICU) admission in diabetic patients admitted with septic shock.
Methods
This retrospective cohort study used electronic medical records and included diabetic patients admitted to the ICU with septic shock. We compared diabetic patients on SGLT2i to those who were not on SGLT2i prior to admission. The primary outcome was in-hospital mortality, and secondary outcomes included hospital and ICU length of stay, use of renal replacement therapy, and 28- and 90-day mortality.
Results
A total of 98 diabetic patients was included in the study, 36 in the SGLT2i group and 62 in the non-SGLT2i group. The Sequential Organ Failure Assessment and Acute Physiology and Chronic Health Evaluation III scores were similar in the groups. Inpatient mortality was significantly lower in the SGLT2i group (5.6% vs. 27.4%, P=0.008). There was no significant difference in secondary outcomes.
Conclusions
Our study found that diabetic patients on SGLT2i prior to hospitalization who were admitted to the ICU with septic shock had lower inpatient mortality compared to patients not on SGLT2i. -
Citations
Citations to this article as recorded by
- Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?
Baris Afsar, Rengin Elsurer Afsar, Katherine Tuttle, Krista L. Lentine
Inflammopharmacology.2026; 34(2): 967. CrossRef - Association Between Gliflozins Use and Outcomes in Adults with Sepsis: A Multicenter Retrospective Cohort Study Among Veterans
Justine Tang, Bocheng Jing, Krystal Karunungan, Anusha Badathala, Arthur Wallace, Matthieu Legrand
Annals of Intensive Care.2026; 16: 100021. CrossRef - Pleiotropic mechanisms and translational trajectory of SGLT2 inhibitors in sepsis-induced cardiomyopathy: Navigating the evidence hierarchy
Xinge Zhang, Liuyi Ren, Min Li, Xiangyu Li, Bimin Feng, Shurong Wang, Xuping Yang, Yilan Huang
European Journal of Pharmacology.2026; 1023: 178858. CrossRef - Melioidosis in people living with diabetes; clinical presentation, clinical course and implications for patient management
Laura Prideaux, Megan Sandeman, Hayley Stratton, Anthony D Kelleher, Simon Smith, Josh Hanson
Acta Tropica.2025; 263: 107559. CrossRef - High-density lipoprotein: a biomarker and therapeutic target in sepsis
Mohan Li, Marina Barros-Pinkelnig, Sesmu M. Arbous, Christina Christoffersen, Patrick C. N. Rensen, Sander Kooijman
Critical Care.2025;[Epub] CrossRef
- Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?
First
Prev
